BTK and B-cell chronic lymphocytic leukemia: Among the second generation of BTK inhibitors that were more recently deeply explored for CLL treatment, Acalabrutinib and the dual BTK/TEC inhibitor Tirabrutinib also appear capable of inhibiting osteoclasts generation [94,95].